Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis

Non-alcoholic fatty liver disease (NAFLD) is the emerging cause of chronic liver disease globally and lack of approved therapies. Here, we investigated the feasibility of combinatorial effects of low molecular weight fucoidan and high stability fucoxanthin (LMF-HSFx) as a therapeutic approach agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Ping-Hsiao, Shiue, Sheng-Jie, Chen, Chun-Nan, Cheng, Sheng-Wei, Lin, Hsin-Yi, Wu, Li-Wei, Wu, Ming-Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001566/
https://www.ncbi.nlm.nih.gov/pubmed/33809062
http://dx.doi.org/10.3390/md19030148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001566/
https://www.ncbi.nlm.nih.gov/pubmed/33809062
http://dx.doi.org/10.3390/md19030148

Ejemplares similares